Celator Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
November 18, 2008 by admin · Leave a Comment
Randomized study will enroll newly diagnosed, elderly AML patients
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
A potential new way to make a good anti-leukemia drug even better
October 20, 2008 by admin · Leave a Comment
A recently identified cancer-causing protein makes the anti-leukemia drug imatinib, less effective. By blocking the protein, an international team of researchers was able to slow the spread of leukemia cells in culture. The study, which will appear online on October 20 in the Journal of Experimental Medicine, suggests that the most effective treatment for leukemia may rely on a combination of targeted drugs, rather than a single miracle drug.
New Leukemia Signal Could Point Way To Better Treatment
September 19, 2008 by admin · Leave a Comment
Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel “double agent” role for a molecular signal that regulates cell growth.
Tumor-inhibiting protein could be effective in treating leukemia
July 15, 2008 by admin · Leave a Comment
Angiocidin also shown to stimulate the body’s immune system
Angiocidin, a tumor-inhibiting novel protein discovered by Temple University researchers, may also have a role as a new therapeutic application in treating leukemia, according to a study by the researchers.
Math could help cure leukemia
June 20, 2008 by admin · Leave a Comment
When kids complain that math homework won’t help them in real life, a new answer might be that math could help cure cancer.
In a recent study that combined math and medicine, researchers have shown that patients with chronic myelogenous leukemia (CML) may be cured of the disease with an optimally timed cancer vaccine, where the timing is determined based on their own immune response.
New drug combination brings 1-2 punch against acute leukemia
May 16, 2008 by admin · Leave a Comment
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation.
In a preclinical study, Lauren Akers, D.O., postdoctoral fellow from the Children’s Cancer Hospital at M. D. Anderson, found that combining a novel glycolysis inhibitor, 3-BrOP, with mTOR inhibitor, rapamycin, induced more than 90 percent cell death in human tissue cultures of acute lymphocytic leukemia. She presented her study at the American Society of Pediatric Hematology/Oncology annual conference on May 16.
Novel mechanism found that may boost impaired function of leukemia protein
March 2, 2008 by admin · Leave a Comment
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells. The findings are published in the March 1, 2008, issue of Genes & Development.
Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
December 11, 2007 by admin · Leave a Comment
Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis. The results of the retrospective study, which sought to quantify the risk factors for leukemic transformation, were presented by lead author Jocelin Huang, M.D., at the American Society of Hematologys annual meeting.
Researcher develops test for targeted therapy in acute myeloid leukemia
December 11, 2007 by admin · Leave a Comment
Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days. This research will be presented at the American Society of Hematology annual meeting in Atlanta, on Monday, Dec. 10, at 8:15 a.m.
Drug has ability to cure type of leukemia
October 8, 2007 by admin · Leave a Comment
Imatinib can kill cancerous stem cells if given enough time, study says
Irvine, Calif. In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped. New research by UC Irvine scientists indicates that Imatinib could cure CML under certain circumstances if it is taken over a long enough period of time.
